ECSP034558A - Moduladores del receptor estrogeno - Google Patents

Moduladores del receptor estrogeno

Info

Publication number
ECSP034558A
ECSP034558A EC2003004558A ECSP034558A ECSP034558A EC SP034558 A ECSP034558 A EC SP034558A EC 2003004558 A EC2003004558 A EC 2003004558A EC SP034558 A ECSP034558 A EC SP034558A EC SP034558 A ECSP034558 A EC SP034558A
Authority
EC
Ecuador
Prior art keywords
strogen
receiver modulators
modulators
receiver
graph
Prior art date
Application number
EC2003004558A
Other languages
English (en)
Spanish (es)
Inventor
Frank P Dininno
Jane Y Wu
Seongkon Kim
Helen Y Chen
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP034558A publication Critical patent/ECSP034558A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08Six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
EC2003004558A 2000-10-19 2003-04-17 Moduladores del receptor estrogeno ECSP034558A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24158200P 2000-10-19 2000-10-19

Publications (1)

Publication Number Publication Date
ECSP034558A true ECSP034558A (es) 2003-06-25

Family

ID=22911282

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004558A ECSP034558A (es) 2000-10-19 2003-04-17 Moduladores del receptor estrogeno

Country Status (20)

Country Link
EP (1) EP1333827A2 (no)
JP (1) JP2004511502A (no)
KR (1) KR20030042020A (no)
CN (1) CN1469743A (no)
AU (2) AU3238102A (no)
BG (1) BG107676A (no)
BR (1) BR0114689A (no)
CA (1) CA2424729A1 (no)
EA (1) EA200300474A1 (no)
EC (1) ECSP034558A (no)
EE (1) EE200300153A (no)
HU (1) HUP0303563A2 (no)
IL (1) IL154984A0 (no)
IS (1) IS6761A (no)
MX (1) MXPA03003485A (no)
NO (1) NO20031737L (no)
PE (1) PE20021083A1 (no)
PL (1) PL361053A1 (no)
SK (1) SK4772003A3 (no)
WO (1) WO2002032377A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
WO2003091239A1 (en) 2002-04-24 2003-11-06 Merck & Co., Inc. Estrogen receptor modulators
AU2003292625B2 (en) * 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
AU2006275514B2 (en) 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CA2627139A1 (en) * 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
CA2676984C (en) 2007-02-01 2015-03-17 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
KR101892987B1 (ko) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 신규한 소염제
KR101698238B1 (ko) 2010-06-10 2017-01-19 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조정제 및 이의 용도
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Also Published As

Publication number Publication date
CA2424729A1 (en) 2002-04-25
EA200300474A1 (ru) 2003-10-30
MXPA03003485A (es) 2003-07-14
WO2002032377A3 (en) 2002-08-22
WO2002032377A2 (en) 2002-04-25
PL361053A1 (en) 2004-09-20
BG107676A (bg) 2003-11-28
KR20030042020A (ko) 2003-05-27
BR0114689A (pt) 2003-07-01
JP2004511502A (ja) 2004-04-15
NO20031737D0 (no) 2003-04-15
AU2002232381B2 (en) 2004-11-18
CN1469743A (zh) 2004-01-21
EE200300153A (et) 2003-06-16
IS6761A (is) 2003-03-27
IL154984A0 (en) 2003-10-31
NO20031737L (no) 2003-06-19
SK4772003A3 (en) 2003-08-05
PE20021083A1 (es) 2002-12-16
EP1333827A2 (en) 2003-08-13
AU3238102A (en) 2002-04-29
HUP0303563A2 (hu) 2004-03-01

Similar Documents

Publication Publication Date Title
ECSP034558A (es) Moduladores del receptor estrogeno
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
DE69925133D1 (de) Pyrrolobenzodiazepine
ECSP034600A (es) Compuestos de lactama
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
ECSP024382A (es) Inhibidores de proteasa de serina
PA8567001A1 (es) Composicion de ziprasidona y controles sinteticos
PE20020108A1 (es) Estructuras y composiciones que aumentan la estabilidad de activos de peroxido
JO2410B1 (en) 6. Replaced pyrido-pyrimidines
TR200102856T1 (tr) Antitümör ajanları olarak C7 ester ikameli taksanlar.
ATE288039T1 (de) Federelement
PA8553101A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
DOP2002000371A (es) Fenil-heterociclil-eteres
RS50002B (sr) Eletriptan hidrobromid monohidrat
MY128164A (en) Compounds
SV2003001179A (es) Formulacion de 2-metilo-tieno-benzodiacepina liofilizada ref. x-11102
BR0114065A (pt) Triazolo-epotilonas
ATE401325T1 (de) C10-carbamoyloxysubstituierte taxane als antitumormittel
DK1165549T3 (da) C7 carbamoyloxy-substituerede taxaner som antitumormidler
BR0313400A (pt) N-aril-2-oxazolidinonas e seus derivados
DOP2000000050A (es) Composición antidecoloracion
BR0113202A (pt) Compostos de trioxepano
ECSP045116A (es) Composicion de jabon transparente estabilizada
DE50212676D1 (de) Exopolysaccharidproduktion